The expanding vaccine development pipeline, 1995-2008

Matthew M. Davis*, Amy T. Butchart, Margaret S. Coleman, Dianne C. Singer, John R C Wheeler, Angela Pok, Gary L. Freed

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


Successful launches of recently licensed vaccines contrast with pharmaceutical industry concerns about unfavorable market conditions, making the status and future of vaccine development uncertain. We assessed trends in private-sector vaccine research and development for the period 1995-2008, using a global pharmaceutical database to identify prophylactic vaccines in preclinical, Phase I, Phase II, or Phase III stages of development. We counted companies that research and/or manufacture vaccines ("vaccine originators") and their vaccine products in each year. The global number of vaccine originators doubled (to 136), as did the number of prophylactic vaccine products in development (to 354); the majority of this growth was in preclinical and early phase clinical research. Because rapid growth in earlier research phases has not yet led to growth in Phase III, it is not yet clear whether recent industry expansion will translate to an increase in the number of available vaccines in the near future.

Original languageEnglish (US)
Pages (from-to)1353-1356
Number of pages4
Issue number5
StatePublished - Feb 3 2010


  • Clinical trials
  • Industry
  • Vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases


Dive into the research topics of 'The expanding vaccine development pipeline, 1995-2008'. Together they form a unique fingerprint.

Cite this